Alpha 2.0
Login Register
» Articles » PMID: 19917747

Panel of Prototypical Raltegravir-resistant Infectious Molecular Clones in a Novel Integrase-deleted Cloning Vector

Overview
Journal Antimicrob Agents Chemother
Publisher American Society for Microbiology
Specialty Pharmacology
Date 2009 Nov 18
PMID 19917747
Citations 19
Authors
Elizabeth C Reuman
Michael H Bachmann
Vici Varghese
W Jeffrey Fessel
Robert W Shafer
Affiliations
Soon will be listed here.
Abstract

We created an HIV-1 cloning vector, pNL4.3DeltaIN, to generate recombinant infectious molecular clones for analysis of patient-derived HIV-1 integrase coding regions. Using this vector, we constructed a panel of clinically derived viruses with the canonical patterns of raltegravir resistance mutations and submitted the panel to the NIH AIDS Research and Reference Reagent Program. Investigational integrase inhibitors with activity against these clones are likely to retain activity against the most clinically relevant raltegravir-resistant variants.

Citing Articles

C-28 linker length modulates the activity of second-generation HIV-1 maturation inhibitors.

Yuvraj K, Kc Y, Singh A, Datta S, Das R, Saxena P Virol J. 2025; 22(1):20.

PMID: 39875943 PMC: 11776332. DOI: 10.1186/s12985-025-02635-8.

Discovery of new acetamide derivatives of 5-indole-1,3,4-oxadiazol-2-thiol as inhibitors of HIV-1 Tat-mediated viral transcription.

Shin Y, Park C, Kim D, Kim S, Lee S, Lee J Antimicrob Agents Chemother. 2024; 68(10):e0064324.

PMID: 39230310 PMC: 11459959. DOI: 10.1128/aac.00643-24.

Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the Potency of Cabotegravir or Rilpivirine.

Jeffrey J, St Clair M, Wang P, Wang C, Li Z, Beloor J Antimicrob Agents Chemother. 2022; 66(3):e0170221.

PMID: 34978890 PMC: 8923183. DOI: 10.1128/AAC.01702-21.

Design, synthesis, and antiviral activity of a series of CD4-mimetic small-molecule HIV-1 entry inhibitors.

Curreli F, Ahmed S, Benedict Victor S, Iusupov I, Spiridonov E, Belov D Bioorg Med Chem. 2021; 32:116000.

PMID: 33461144 PMC: 7856678. DOI: 10.1016/j.bmc.2021.116000.

Preclinical Optimization of gp120 Entry Antagonists as anti-HIV-1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation.

Curreli F, Ahmed S, Benedict Victor S, Iusupov I, Belov D, Markov P J Med Chem. 2020; 63(4):1724-1749.

PMID: 32031803 PMC: 7703574. DOI: 10.1021/acs.jmedchem.9b02149.

References
1.
Deeks S, Wrin T, Liegler T, Hoh R, Hayden M, Barbour J . Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med. 2001; 344(7):472-80. DOI: 10.1056/NEJM200102153440702. View
2.
Fransen S, Gupta S, Danovich R, Hazuda D, Miller M, Witmer M . Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol. 2009; 83(22):11440-6. PMC: 2772690. DOI: 10.1128/JVI.01168-09. View
3.
Lennox J, DeJesus E, Lazzarin A, Pollard R, Madruga J, Berger D . Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009; 374(9692):796-806. DOI: 10.1016/S0140-6736(09)60918-1. View
4.
Steigbigel R, Cooper D, Kumar P, Eron J, Schechter M, Markowitz M . Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008; 359(4):339-54. DOI: 10.1056/NEJMoa0708975. View
5.
Rhee S, Liu T, Kiuchi M, Zioni R, Gifford R, Holmes S . Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors. Retrovirology. 2008; 5:74. PMC: 2546438. DOI: 10.1186/1742-4690-5-74. View